Drug firm Lupin has received approval from the Central Drugs Standard Control Organisation (CDSCO) for Bepotastine tablets used in the treatment of patients suffering from allergic symptoms.
Bepotastine is a new second generation antihistamine medicine to be introduced into the Indian Pharmaceutical Market (IPM), which could benefit millions of patients suffering from allergic symptoms.
It is a rapid acting antihistamine that effectively controls day time and night time triggers of allergic symptoms. Bepotastine is approved by PMDA Japan and is actively marketed in Japan and other South-East Asian countries.
The current market for plain antihistamines is estimated to be around Rs. 860 crore, growing at 14 per cent.